Sanofi gets EC approval for recombinant influenza vaccine Supemtek
France-based Sanofi has secured the European Commission (EC) approval to market its quadrivalent recombinant vaccine Supemtek, against influenza in adults aged 18 years and above. The French pharmaceutical